西安康拓医疗技术股份有限公司 第二届董事会第十七次会议决议公告

Group 1 - The company held its 17th meeting of the second board on June 12, 2025, with all 9 directors present, confirming the legality and effectiveness of the meeting [2][3][4] - The board approved the adjustment of the 2025 restricted stock incentive plan, reducing the number of initial grant recipients from 55 to 54 and adjusting the grant price from 14.68 yuan to 14.50 yuan per share [3][4][15] Group 2 - The company will grant 1.3 million shares of restricted stock to 54 recipients at a price of 14.50 yuan per share, effective June 12, 2025, which represents 1.60% of the company's total share capital [23][24] - The adjustment of the grant price was necessitated by a cash dividend distribution of 0.18 yuan per share, leading to a recalculation of the grant price [16][18] Group 3 - The company confirmed that the adjustments to the incentive plan will not materially affect its financial status or operational results [19] - The remuneration and assessment committee reviewed and approved the adjustments, ensuring compliance with relevant regulations [20][21]